One-step Derivation of Functional Mesenchymal Stem Cells from Human Pluripotent Stem Cells
| Autor: | Fang Chongzhou, Yan Zhou, Yonglun Luo, Mo Cuiping, Jinqi Liao, Guangqian Zhou |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Strategy and Management Mechanical Engineering Cell Mesenchymal stem cell Metals and Alloys Embryoid body Biology Chondrogenesis Embryonic stem cell Regenerative medicine Industrial and Manufacturing Engineering Cell biology 03 medical and health sciences 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure Tissue engineering 030220 oncology & carcinogenesis medicine Methods Article Induced pluripotent stem cell |
| Zdroj: | Bio Protoc |
| Popis: | Mesenchymal stem cells (MSCs) are invaluable cell sources for understanding stem cell biology and potential application in tissue engineering and regenerative medicine. The current issues of MSCs that demand to be further addressed are limited donors, tissue sources and limited capacity of ex vivo expansion. Here, we describe a simple and easy protocol for generating functional mesenchymal stem cells from human pluripotent stem cells (hPSCs) via one-step low glucose medium switch strategy in feeder-free culture system. In this protocol, human induced pluripotent stem cells (hiPSCs) and H9 human embryonic stem cells (hESCs) were successfully differentiated into MSCs, named hiPSC-MSCs and hESC-MSCs, respectively. The derived hiPSC-MSCs and hESC-MSCs exhibited common MSC characteristics as MSCs derived from human bone marrow (hBM-MSCs), including expressing MSC surface markers and possessing capability of tri-lineage differentiation in vitro (adipogenesis, osteogenesis and chondrogenesis). As compared with other available protocols, our protocol can be applied to generate a large number of MSCs from hPSCs with high efficiency, low-cost manner, moreover, not involving embryoid body, mouse feeder-cell, flow sorting, and pathway inhibitors (such as SB203580 and SB431542). We believe that this protocol could provide a robust platform to reach the future demand for producing the industrial scale of MSC from hPSCs for autologous cell-based therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|